Skip to content
value.today

Annovis Bio, Inc.

ANVS
$63 Mmarket cap on Oct 30, 2026-66.7% since Jan 2024
Compare
World rank
#20,449
Revenue
—
For year ending December-2025
Net income
$-29 M
SEC filing
Employees
—

Annovis Bio, Inc. in brief

Annovis Bio, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2008. Its market value was $63 M on 30 October 2026, which makes it the 20,449th largest listed company in the world and the 3,755th largest in the USA on this site. Maria-Luisa Maccecchini is its chief executive. Its shares trade under the symbol ANVS (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Annovis Bio, Inc.

We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease and Parkinson’s disease. We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ, tau/phospho-tau, α-Synuclein and TDP43 — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our completed clinical studies in AD and PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.

From the company's annual report filed with the US SEC: read the report

Annovis Bio, Inc. timeline

4 events, 2008–2020
  1. 2008
  2. 🏁
    · approximate
    Founded
  3. 2010
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2019
  6. ✎
    Renamed Annovis Bio, Inc.
    Formerly QR Pharma, Inc..
  7. 2020
  8. 🔔
    Initial public offering on NYSE
    Final prospectus filed with the SEC on 30 January 2020; shares registered for exchange trading on 28 January 2020.

Events of Annovis Bio, Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$51 M$103 M$154 M$205 M202120222023202420252026

World rank over time

▲ up 42 places since 2021
2021-01-01: #20529#20,52920212022-01-07: #20812#20,81220222022-12-25: #21263#21,26320222023-07-30: #20771#20,77120232024-01-05: #18167#18,16720242026-03-08: #10575#10,57520262026-08-01: #18749#18,74920262026-10-14: #20421#20,42120262026-10-30: #20487#20,4872026

Rank in USA: #4,031 (Jan 2021) · #4,166 (Jan 2022) · #4,228 (Dec 2022) · #4,062 (Jul 2023) · #3,293 (Jan 2024) · #2,068 (Mar 2026) · #3,644 (Aug 2026) · #3,724 (Oct 2026) · #3,759 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.8×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-171.2%
Liabilities / assets
20.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-1M—FY19Fiscal year ending Dec 2020: revenue —, net income $-5M—FY20Fiscal year ending Dec 2021: revenue —, net income $-14M—FY21Fiscal year ending Dec 2022: revenue —, net income $-25M—FY22Fiscal year ending Dec 2023: revenue —, net income $-56M—FY23Fiscal year ending Dec 2024: revenue —, net income $-25M—FY24Fiscal year ending Dec 2025: revenue —, net income $-29M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-30M$-29M—
Dec 2024——$-27M$-25M—
Dec 2023——$-45M$-56M—
Dec 2022——$-26M$-25M—
Dec 2021——$-15M$-14M—
Dec 2020——$-7M$-5M—
Dec 2019——$-2M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-26M——$-1.40—
Dec 2024$-22M——$-2.31—
Dec 2023$-40M——$-6.23—
Dec 2022$-17M——$-3.10—
Dec 2021$-9M——$-1.90—
Dec 2020$-4M——$-0.87—
Dec 2019$-0M——$-3.51—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-6M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-7M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-10M—Dec ’25Three months to Mar 2026: revenue —, net income $-18M—Mar ’26Three months to Jun 2026: revenue —, net income $-15M—Jun ’26Three months to Sep 2026: revenue —, net income $-9M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Annovis Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-30 M
Net income
$-29 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$21 M
Total liabilities
$4 M
Total equity
$17 M

As of December-2025

Top 60 institutional investors in Annovis Bio, Inc.#

As of Sep 30, 2026
60 institutions held 7.4 M shares (about 17.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 14.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Annovis Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Marshall Wace, LLP1,701,241-141,098 (-7.66%)3.99%$2 MNov 13, 2026
2Vanguard Capital Management LLC1,581,689-65,633 (-3.98%)3.71%$2 MNov 13, 2026
3Two Sigma Investments, LP748,234+168,663 (+29.10%)1.76%$1 MNov 16, 2026
4Renaissance Technologies LLC736,027-266,173 (-26.56%)1.73%$1 MNov 12, 2026
5Geode Capital Management, LLC324,422+40,605 (+14.31%)0.76%$0 MNov 6, 2026
6BlackRock, Inc.245,096-4,760 (-1.91%)0.58%$0 MNov 13, 2026
7Susquehanna International Group, LLP243,163+96,359 (+65.64%)0.57%$0 MNov 16, 2026
8Vanguard Fiduciary Trust Co224,236+46,706 (+26.31%)0.53%$0 MNov 13, 2026
9Gsa Capital Partners LLP218,398+168,494 (+337.64%)0.51%$0 MNov 16, 2026
10Citadel Advisors LLC211,892-31,790 (-13.05%)0.50%$0 MNov 16, 2026
11Morgan Stanley199,351+199,010 (+58360.70%)0.47%$0 MNov 13, 2026
12UBS Group AG114,602+102,827 (+873.27%)0.27%$0 MNov 10, 2026
13Greenwich Wealth Management LLC112,800+64,400 (+133.06%)0.26%$0 MNov 12, 2026
14State Street Corp105,335+27,600 (+35.51%)0.25%$0 MNov 12, 2026
15Northern Trust Corp68,0700 (0.00%)0.16%$0 MNov 16, 2026
16Sherry Group, Inc.57,2700 (0.00%)0.13%$0 MOct 9, 2026
17Wescott Financial Advisory Group, LLC41,6070 (0.00%)0.10%$0 MNov 9, 2026
18Bridgeway Capital Management, LLC37,114-563 (-1.49%)0.09%$0 MNov 16, 2026
19Empowered Funds, LLC33,014New0.08%$0 MNov 13, 2026
20Dakota Wealth Management29,0000 (0.00%)0.07%$0 MNov 12, 2026
21CWA Asset Management Group, LLC28,000-1 (0.00%)0.07%$0 MOct 19, 2026
22Wells Fargo & Company/mn27,247-3,060 (-10.10%)0.06%$0 MNov 16, 2026
23StoneX Group Inc.23,996+9,531 (+65.89%)0.06%$0 MNov 3, 2026
24Sterling Investment Advisors, Ltd.23,4160 (0.00%)0.06%$0 MOct 27, 2026
25Wealthspire Advisors, LLC20,0000 (0.00%)0.05%$0 MNov 13, 2026
Show all 60: investors 26 to 60
Institutional investors 26 to 60 in Annovis Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nicholson Wealth Management Group, LLC20,000New0.05%$0 MNov 9, 2026
27Jpmorgan Chase & Co19,900+4,681 (+30.76%)0.05%$0 MNov 12, 2026
28Gill Capital Partners, LLC18,5790 (0.00%)0.04%$0 MOct 13, 2026
29Robertson Stephens Wealth Management, LLC18,5790 (0.00%)0.04%$0 MOct 16, 2026
30R Squared Ltd17,698New0.04%$0 MNov 6, 2026
31Squarepoint Ops LLC16,769New0.04%$0 MNov 9, 2026
32Quadcap Wealth Management, LLC16,1100 (0.00%)0.04%$0 MNov 2, 2026
33Bank of New York Mellon Corp15,4760 (0.00%)0.04%$0 MNov 5, 2026
34Tower Research Capital LLC (TRC)15,217New0.04%$0 MNov 16, 2026
35Vanguard Global Advisers, LLC11,1900 (0.00%)0.03%$0 MNov 13, 2026
36RKL Wealth Management LLC10,0000 (0.00%)0.02%$0 MOct 16, 2026
37Wilmington Savings Fund Society, FSB9,3930 (0.00%)0.02%$0 MOct 23, 2026
38Osaic Holdings, Inc.6,640+6,430 (+3061.90%)0.02%$0 MNov 12, 2026
39Royal Bank Of Canada6,600+1,000 (+17.86%)0.02%$0 MNov 16, 2026
40Arax Advisory Partners6,5000 (0.00%)0.02%$0 MNov 12, 2026
41Gallacher Capital Management LLC5,7050 (0.00%)0.01%$0 MOct 30, 2026
42Covestor Ltd4,863+229 (+4.94%)0.01%$0 MOct 30, 2026
43PNC Financial Services Group, Inc.2,960+2,600 (+722.22%)0.01%$0 MNov 6, 2026
44Pinnacle Financial Group, Inc.2,400—0.01%$0 MNov 16, 2026
45CoreCap Advisors, LLC2,1010 (0.00%)0.00%$0 MOct 8, 2026
46Nuveen, LLC1,861New0.00%$0 MNov 10, 2026
47SBI Securities Co., Ltd.1,572+25 (+1.62%)0.00%$0 MOct 22, 2026
48Keating Financial Advisory Services, Inc.1,0820 (0.00%)0.00%$0 MNov 12, 2026
49Rockefeller Capital Management L.P.1,0000 (0.00%)0.00%$0 MNov 13, 2026
50DiNuzzo Private Wealth, Inc.1,0000 (0.00%)0.00%$0 MOct 16, 2026
51Bokf, NA5550 (0.00%)0.00%$0 MOct 27, 2026
52Steward Partners Investment Advisory, LLC500-1,345 (-72.90%)0.00%$0 MNov 13, 2026
53Rialto Wealth Management, LLC483+214 (+79.55%)0.00%$0 MNov 16, 2026
54Larson Financial Group LLC3000 (0.00%)0.00%$0 MNov 5, 2026
55IFP Advisors, Inc1100 (0.00%)0.00%$0 MOct 16, 2026
56Global Retirement Partners, LLC1000 (0.00%)0.00%$0 MNov 10, 2026
57Caitong International Asset Management Co., Ltd52+46 (+766.67%)0.00%$0 MOct 29, 2026
58Northwestern Mutual Wealth Management Co200 (0.00%)0.00%$0 MNov 13, 2026
59Russell Investments Group, Ltd.1New0.00%$0 MNov 6, 2026
60Blue Trust, Inc.1New0.00%$0 MOct 15, 2026

Mutual funds holding Annovis Bio, Inc.#

11 funds hold shares worth $4 M (about 4.7% of the company). Since their previous reports 8 added shares and 5 sold, buying $2 M net.
Mutual funds holding Annovis Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.22 M$2 M2.9%<0.01%+106%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.393,887$1 M0.92%<0.01%+55%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC123,461$0 M0.29%<0.01%+1.0%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors103,332$0 M0.24%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC34,459$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC33,419$0 M0.08%<0.01%+8.6%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC33,577$0 M0.08%0.04%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.20,994$0 M0.05%<0.01%+59%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.12,723$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC6,991$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC557$0 M<0.01%<0.01%+12%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Annovis Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$7.1 M
13 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$7.1 M
open market only
Insiders on file
9
since
$5.0 M$0Oct 2025: bought $2.2 M (2 trades), sold $0 (0 trades)Oct 25Nov 2025: bought $261 K (7 trades), sold $0 (0 trades)NovDec 2025: bought $194 K (2 trades), sold $0 (0 trades)DecApr 2026: bought $1.5 M (1 trades), sold $0 (0 trades)AprMay 2026: bought $143 K (3 trades), sold $0 (0 trades)MayNov 2026: bought $5.0 M (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Annovis Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Michael B. HoffmanDirectorBuy+5.00 M$1.000$5.0 M8.36 MForm 4
filed Michael B. HoffmanDirectorBuy+2,562$1.750$4 K3.29 MForm 4
filed Michael B. HoffmanDirectorBuy+18,849$1.800$34 K3.31 MForm 4
filed Michael B. HoffmanDirectorBuy+54,933$1.900$104 K3.36 MForm 4
filed Michael B. HoffmanDirectorBuy+713,800$2.100$1.5 M3.29 MForm 4
filed Michael B. HoffmanDirectorBuy+30,000$4.340$130 K2.56 MForm 4
filed Michael B. HoffmanDirectorBuy+15,000$4.240$64 K2.57 MForm 4
filed Michael B. HoffmanDirectorBuy+1,489$4.130$6 K2.48 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Annovis Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.4 M
19.7% of shares · 6.77 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 37,968 shares at $1.02
  • : 39,168 shares at $1.02
  • : 42,825 shares at $0.98
  • : 27,231 shares at $0.99
  • : 18,312 shares at $1.06

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Annovis Bio, Inc. scorecard#

Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.8×Price to book 3.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.40 vs -2.31Diluted EPS -1.40 in fiscal 2025 against -2.31 the year before (report's currency).
    • ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$5 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-220.6%-220.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year68.0%Diluted shares up 68.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Annovis Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Annovis Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue0000000
Research and development252039178.53.10.8
General and administrative4.56.76.29.06.13.60.8
Operating expenses30274526156.61.6
Operating income−30−27−45−26−15−6.6−1.6
Interest and finance income0.70.30.7————
Other non-operating income (expense)0.82.1−110.20.11.20.6
Income before tax——−56−25−14−5.5−1.0
Income tax0—————0
Net income including minority interests−29−25−56−25−14−5.5−1.0
Net income attributable to shareholders−29−25−56−25−14−5.5−1.0
Earnings per share, basic-1.40-2.02-6.23-3.10-1.90-0.87-3.51
Earnings per share, diluted-1.40-2.31-6.23-3.10-1.90-0.87-3.51
Shares, weighted average (basic)21129.08.27.66.3—
Shares, weighted average (diluted)21129.08.27.66.30.3
Balance sheet
Cash and cash equivalents20115.828468.10.0
Current assets——1036468.10.7
Non-current assets——————0.4
Total assets21141036468.11.1
Accounts payable2.62.31.34.00.70.31.2
Current liabilities3.63.94.37.71.50.62.0
Non-current liabilities——————0.6
Total liabilities4.24.6187.71.50.62.6
Retained earnings−164−135−110−54−29−14−8.8
Shareholders' equity179.3−7.828447.5−8.6
Total liabilities and equity21141036468.11.1
Shares outstanding2714118.28.16.90.3
Cash-flow statement
Share-based compensation1.83.84.69.24.71.90.0
Cash from operating activities−26−22−40−17−9.1−4.0−0.5
Shares issued—1917—4712—
Cash from financing activities3527170.047120.4
Change in cash9.04.8−23−17388.1−0.0
Report10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Annovis Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 5 · Material agreement 7 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8

Annovis Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Directors and officersResults announced8-K
Delisting noticeDirectors and officers8-K
Results announced8-K
Material agreement8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Annovis Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$1 MPrivate placement after listingUnder $2 million6equitySEC
May 2015$1 MNo. 1Under $2 million21equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Annovis Bio, Inc. compares in Biotechnology

  • Market cap$63 M · higher than 29% of 726
  • Price / book3.8× · lower than 40% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Annovis Bio, Inc.🇺🇸$63 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Annovis Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Annovis Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Annovis Bio, Inc.? Suggest a correction